Morgan Stanley Lowers Stevanato Group (NYSE:STVN) Price Target to $19.00

Stevanato Group (NYSE:STVN) had its price objective lowered by research analysts at Morgan Stanley from $24.00 to $19.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock.

A number of other equities analysts have also issued reports on the stock. Wall Street Zen lowered shares of Stevanato Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Citigroup lowered their price target on shares of Stevanato Group from $32.00 to $26.00 and set a “buy” rating for the company in a report on Thursday. Jefferies Financial Group set a $17.50 price objective on Stevanato Group in a report on Tuesday, February 10th. KeyCorp decreased their price objective on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating on the stock in a research report on Thursday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Stevanato Group in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

Stevanato Group Stock Down 2.8%

Shares of NYSE:STVN opened at €15.46 on Friday. The company has a quick ratio of 1.30, a current ratio of 1.76 and a debt-to-equity ratio of 0.23. The firm has a market cap of $4.68 billion, a P/E ratio of 26.66, a P/E/G ratio of 1.42 and a beta of 0.57. Stevanato Group has a 12 month low of €13.91 and a 12 month high of €28.00. The company’s 50-day moving average price is €17.58 and its two-hundred day moving average price is €21.65.

Institutional Investors Weigh In On Stevanato Group

Several institutional investors have recently modified their holdings of the business. Royal Bank of Canada boosted its stake in Stevanato Group by 10.8% in the first quarter. Royal Bank of Canada now owns 437,284 shares of the company’s stock valued at $8,930,000 after acquiring an additional 42,731 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Stevanato Group by 4.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 170,002 shares of the company’s stock valued at $4,153,000 after purchasing an additional 7,232 shares during the period. First Horizon Advisors Inc. boosted its position in shares of Stevanato Group by 14.9% in the 2nd quarter. First Horizon Advisors Inc. now owns 3,833 shares of the company’s stock worth $94,000 after purchasing an additional 497 shares during the last quarter. Marco Investment Management LLC bought a new position in shares of Stevanato Group in the 2nd quarter worth $228,000. Finally, Zions Bancorporation National Association UT grew its stake in shares of Stevanato Group by 9.2% during the second quarter. Zions Bancorporation National Association UT now owns 102,357 shares of the company’s stock worth $2,501,000 after purchasing an additional 8,648 shares during the period.

Stevanato Group News Summary

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Q4 beats and revenue momentum — Stevanato reported Q4 results that beat expectations (reported EPS ~$0.2114 vs. ~$0.20 consensus) and highlighted strong revenue growth, reinforcing demand for its pharmaceutical packaging and high‑value solutions. STVN Q4 Highlights
• Positive Sentiment: 2026 guidance and HVS mix — Management outlined a 2026 revenue target up to €1.308B and expects high‑value solutions (HVS) to reach ~48% of sales, supporting margin expansion potential as capex is mainly HVS‑directed. 2026 Revenue Target Article
• Positive Sentiment: Analyst buy support — At least one note (Seeking Alpha piece) reiterates a Buy thesis citing Q4/FY25 strength and long‑term demand drivers, framing current weakness as cyclical in the Engineering segment. Stevanato: Strong Q4 Results Reinforce Long-Term Growth Story
• Neutral Sentiment: Earnings call detail — Full Q4/FY25 earnings call transcripts and summaries are available for deeper read; they provide management color on capex allocation (heavy toward HVS) and the cyclical pressure in Engineering. Useful for modeling near‑term margin recovery timing. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Transcripts published — Full call transcripts (Seeking Alpha / InsiderMonkey) confirm the beat and provide verbatim management commentary for investors building scenarios. Earnings Call Transcript
• Negative Sentiment: Multiple analyst price‑target cuts — Morgan Stanley cut its PT to $19 and moved to Equal Weight; Citigroup lowered its PT to $26 (maintained Buy); KeyCorp trimmed its PT to $32 (keeps Overweight). Those revisions reduce near‑term upside expectations and likely contributed to selling pressure. Analyst PT Changes (Benzinga) KeyBanc / StreetInsider

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.